Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESS… Read more
Neurocrine Biosciences Inc - Asset Resilience Ratio
Neurocrine Biosciences Inc (NBIX) has an Asset Resilience Ratio of 16.57% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Neurocrine Biosciences Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Neurocrine Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $767.40 Million | 16.57% |
| Total Liquid Assets | $767.40 Million | 16.57% |
Asset Resilience Insights
- Good Liquidity Position: Neurocrine Biosciences Inc maintains a healthy 16.57% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Neurocrine Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Neurocrine Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Neurocrine Biosciences Inc (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Neurocrine Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 16.57% | $767.40 Million | $4.63 Billion | -6.10pp |
| 2024-12-31 | 22.67% | $843.10 Million | $3.72 Billion | -1.33pp |
| 2023-12-31 | 24.01% | $780.50 Million | $3.25 Billion | -6.66pp |
| 2022-12-31 | 30.67% | $726.40 Million | $2.37 Billion | +12.79pp |
| 2021-12-31 | 17.88% | $370.50 Million | $2.07 Billion | -17.51pp |
| 2020-12-31 | 35.39% | $613.90 Million | $1.73 Billion | -7.36pp |
| 2019-12-31 | 42.74% | $558.25 Million | $1.31 Billion | -8.53pp |
| 2018-12-31 | 51.27% | $509.20 Million | $993.15 Million | +19.32pp |
| 2017-12-31 | 31.95% | $261.22 Million | $817.59 Million | -29.43pp |
| 2016-12-31 | 61.38% | $224.08 Million | $365.09 Million | -2.86pp |
| 2015-12-31 | 64.24% | $305.00 Million | $474.79 Million | -2.75pp |
| 2014-12-31 | 66.98% | $162.79 Million | $243.03 Million | +1.72pp |
| 2013-12-31 | 65.27% | $100.95 Million | $154.68 Million | +9.52pp |
| 2012-12-31 | 55.75% | $109.26 Million | $195.98 Million | -1.34pp |
| 2011-12-31 | 57.09% | $79.00 Million | $138.37 Million | +6.67pp |
| 2010-12-31 | 50.42% | $72.81 Million | $144.42 Million | +27.63pp |
| 2009-12-31 | 22.78% | $16.14 Million | $70.82 Million | +12.62pp |
| 2008-12-31 | 10.16% | $12.01 Million | $118.18 Million | -18.66pp |
| 2007-12-31 | 28.82% | $79.72 Million | $276.65 Million | +2.74pp |
| 2006-12-31 | 26.08% | $101.62 Million | $389.68 Million | -20.10pp |
| 2005-12-31 | 46.18% | $223.12 Million | $483.12 Million | -0.06pp |
| 2004-12-31 | 46.24% | $240.10 Million | $519.22 Million | -16.34pp |
| 2003-12-31 | 62.58% | $347.31 Million | $554.96 Million | -12.60pp |
| 2002-12-31 | 75.18% | $200.40 Million | $266.54 Million | +30.12pp |
| 2001-12-31 | 45.07% | $156.09 Million | $346.35 Million | -32.15pp |
| 2000-12-31 | 77.22% | $143.59 Million | $185.96 Million | +13.30pp |
| 1999-12-31 | 63.92% | $69.80 Million | $109.20 Million | -- |